Literature DB >> 8876906

Supratentorial low-grade glioma: is there a role for radiation therapy?

T G Trautmann1, E G Shaw.   

Abstract

The supratentorial low-grade gliomas are a heterogeneous group of central nervous system tumours. Knowledge of their biology, primarily based on histologic subtype and patient age, is helpful in determining prognosis and guiding therapeutic recommendations. The pilocytic tumours usually occur in younger patients and carry a favourable prognosis. Recurrence following gross total excision is rare, and approximately 80% of patients undergoing subtotal removal with or without postoperative radiation therapy (RT) will survive 10 years or longer. In contrast, non-pilocytic, supratentorial low-grade tumours (including the diffuse fibrillary, protoplasmic and gemistocytic subtypes), as well as mixed oligoastrocytomas and oligodendrogliomas are infrequently cured, even with gross total excision. Survival benefit with postoperative RT has been suggested by several retrospective studies. When RT is prescribed, localized treatment fields are suggested for total doses of 4500 to 6500 cGy. Ongoing prospective, randomized studies hopefully will clarify the role of RT in these neoplasms, as well as the optimal dose.

Entities:  

Mesh:

Year:  1996        PMID: 8876906

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  2 in total

1.  The role of MRI in patients with astrocytoma WHO II treated with fractionated stereotactic radiotherapy.

Authors:  Christian Plathow; Matthias Philipp Lichy; Peter Bachert; Ivan Zuna; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2003-11-11       Impact factor: 5.315

2.  Residual Tumor Volume as Best Outcome Predictor in Low Grade Glioma - A Nine-Years Near-Randomized Survey of Surgery vs. Biopsy.

Authors:  Roland Roelz; David Strohmaier; Ramazan Jabbarli; Rainer Kraeutle; Karl Egger; Volker A Coenen; Astrid Weyerbrock; Peter C Reinacher
Journal:  Sci Rep       Date:  2016-08-30       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.